quantitative high resolution orbitrap lc ms analysis  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Thermo Fisher quantitative high resolution orbitrap lc ms analysis
    A metabolite of RIPGBM induces apoptosis in GBM CSCs by interacting with RIPK2. ( A ) <t>Orbitrap</t> MS-based metabolite identification studies in GBM-1 (GBM CSC) or primary HLF cells incubated with RIPGBM (1 μM) for 0, 12, 24, or 48 h. ( B ) Structure of the cyclized RIPGBM metabolite cRIPGBM generated in GBM CSCs. ( C ) Cell survival curves for GBM CSCs (GBM-1), human NPCs, primary human astrocyte cells, and HLFs treated with cRIPGBM for 48 h. ( D ) Structure of PAP reagent cRIPGBM-PAP. ( E ) In vitro binding of cRIPGBM-PAP to recombinant human full-length RIPK2 protein in the presence or absence of competition using underivatized cRIPGBM or RIPGBM. ( F ) Domain structure of RIPK2 and in vitro binding of cRIPGBM-PAP to recombinant full-length, truncated kinase domain, or truncated CARD domain human RIPK2 protein. ( G ) cRIPGBM-induced apoptosis in GBM-1 GBM CSCs following shRNA-mediated RIPK2 gene knockdown. Values shown are mean ± SD (* P
    Quantitative High Resolution Orbitrap Lc Ms Analysis, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/quantitative high resolution orbitrap lc ms analysis/product/Thermo Fisher
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    quantitative high resolution orbitrap lc ms analysis - by Bioz Stars, 2020-07
    93/100 stars

    Related Products / Commonly Used Together

    gbm csc

    Images

    1) Product Images from "A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer"

    Article Title: A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    doi: 10.1073/pnas.1816626116

    A metabolite of RIPGBM induces apoptosis in GBM CSCs by interacting with RIPK2. ( A ) Orbitrap MS-based metabolite identification studies in GBM-1 (GBM CSC) or primary HLF cells incubated with RIPGBM (1 μM) for 0, 12, 24, or 48 h. ( B ) Structure of the cyclized RIPGBM metabolite cRIPGBM generated in GBM CSCs. ( C ) Cell survival curves for GBM CSCs (GBM-1), human NPCs, primary human astrocyte cells, and HLFs treated with cRIPGBM for 48 h. ( D ) Structure of PAP reagent cRIPGBM-PAP. ( E ) In vitro binding of cRIPGBM-PAP to recombinant human full-length RIPK2 protein in the presence or absence of competition using underivatized cRIPGBM or RIPGBM. ( F ) Domain structure of RIPK2 and in vitro binding of cRIPGBM-PAP to recombinant full-length, truncated kinase domain, or truncated CARD domain human RIPK2 protein. ( G ) cRIPGBM-induced apoptosis in GBM-1 GBM CSCs following shRNA-mediated RIPK2 gene knockdown. Values shown are mean ± SD (* P
    Figure Legend Snippet: A metabolite of RIPGBM induces apoptosis in GBM CSCs by interacting with RIPK2. ( A ) Orbitrap MS-based metabolite identification studies in GBM-1 (GBM CSC) or primary HLF cells incubated with RIPGBM (1 μM) for 0, 12, 24, or 48 h. ( B ) Structure of the cyclized RIPGBM metabolite cRIPGBM generated in GBM CSCs. ( C ) Cell survival curves for GBM CSCs (GBM-1), human NPCs, primary human astrocyte cells, and HLFs treated with cRIPGBM for 48 h. ( D ) Structure of PAP reagent cRIPGBM-PAP. ( E ) In vitro binding of cRIPGBM-PAP to recombinant human full-length RIPK2 protein in the presence or absence of competition using underivatized cRIPGBM or RIPGBM. ( F ) Domain structure of RIPK2 and in vitro binding of cRIPGBM-PAP to recombinant full-length, truncated kinase domain, or truncated CARD domain human RIPK2 protein. ( G ) cRIPGBM-induced apoptosis in GBM-1 GBM CSCs following shRNA-mediated RIPK2 gene knockdown. Values shown are mean ± SD (* P

    Techniques Used: Mass Spectrometry, Incubation, Generated, In Vitro, Binding Assay, Recombinant, shRNA

    Related Articles

    Liquid Chromatography with Mass Spectroscopy:

    Article Title: A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer
    Article Snippet: .. Cell pellets and growth media of GBM CSC and control cell types were extracted following drug treatment and subjected to quantitative high-resolution Orbitrap LC-MS analysis (Thermo Fisher Scientific). ..

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Thermo Fisher quantitative high resolution orbitrap lc ms analysis
    A metabolite of RIPGBM induces apoptosis in GBM CSCs by interacting with RIPK2. ( A ) <t>Orbitrap</t> MS-based metabolite identification studies in GBM-1 (GBM CSC) or primary HLF cells incubated with RIPGBM (1 μM) for 0, 12, 24, or 48 h. ( B ) Structure of the cyclized RIPGBM metabolite cRIPGBM generated in GBM CSCs. ( C ) Cell survival curves for GBM CSCs (GBM-1), human NPCs, primary human astrocyte cells, and HLFs treated with cRIPGBM for 48 h. ( D ) Structure of PAP reagent cRIPGBM-PAP. ( E ) In vitro binding of cRIPGBM-PAP to recombinant human full-length RIPK2 protein in the presence or absence of competition using underivatized cRIPGBM or RIPGBM. ( F ) Domain structure of RIPK2 and in vitro binding of cRIPGBM-PAP to recombinant full-length, truncated kinase domain, or truncated CARD domain human RIPK2 protein. ( G ) cRIPGBM-induced apoptosis in GBM-1 GBM CSCs following shRNA-mediated RIPK2 gene knockdown. Values shown are mean ± SD (* P
    Quantitative High Resolution Orbitrap Lc Ms Analysis, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/quantitative high resolution orbitrap lc ms analysis/product/Thermo Fisher
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    quantitative high resolution orbitrap lc ms analysis - by Bioz Stars, 2020-07
    93/100 stars
      Buy from Supplier

    Image Search Results


    A metabolite of RIPGBM induces apoptosis in GBM CSCs by interacting with RIPK2. ( A ) Orbitrap MS-based metabolite identification studies in GBM-1 (GBM CSC) or primary HLF cells incubated with RIPGBM (1 μM) for 0, 12, 24, or 48 h. ( B ) Structure of the cyclized RIPGBM metabolite cRIPGBM generated in GBM CSCs. ( C ) Cell survival curves for GBM CSCs (GBM-1), human NPCs, primary human astrocyte cells, and HLFs treated with cRIPGBM for 48 h. ( D ) Structure of PAP reagent cRIPGBM-PAP. ( E ) In vitro binding of cRIPGBM-PAP to recombinant human full-length RIPK2 protein in the presence or absence of competition using underivatized cRIPGBM or RIPGBM. ( F ) Domain structure of RIPK2 and in vitro binding of cRIPGBM-PAP to recombinant full-length, truncated kinase domain, or truncated CARD domain human RIPK2 protein. ( G ) cRIPGBM-induced apoptosis in GBM-1 GBM CSCs following shRNA-mediated RIPK2 gene knockdown. Values shown are mean ± SD (* P

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer

    doi: 10.1073/pnas.1816626116

    Figure Lengend Snippet: A metabolite of RIPGBM induces apoptosis in GBM CSCs by interacting with RIPK2. ( A ) Orbitrap MS-based metabolite identification studies in GBM-1 (GBM CSC) or primary HLF cells incubated with RIPGBM (1 μM) for 0, 12, 24, or 48 h. ( B ) Structure of the cyclized RIPGBM metabolite cRIPGBM generated in GBM CSCs. ( C ) Cell survival curves for GBM CSCs (GBM-1), human NPCs, primary human astrocyte cells, and HLFs treated with cRIPGBM for 48 h. ( D ) Structure of PAP reagent cRIPGBM-PAP. ( E ) In vitro binding of cRIPGBM-PAP to recombinant human full-length RIPK2 protein in the presence or absence of competition using underivatized cRIPGBM or RIPGBM. ( F ) Domain structure of RIPK2 and in vitro binding of cRIPGBM-PAP to recombinant full-length, truncated kinase domain, or truncated CARD domain human RIPK2 protein. ( G ) cRIPGBM-induced apoptosis in GBM-1 GBM CSCs following shRNA-mediated RIPK2 gene knockdown. Values shown are mean ± SD (* P

    Article Snippet: Cell pellets and growth media of GBM CSC and control cell types were extracted following drug treatment and subjected to quantitative high-resolution Orbitrap LC-MS analysis (Thermo Fisher Scientific).

    Techniques: Mass Spectrometry, Incubation, Generated, In Vitro, Binding Assay, Recombinant, shRNA